Test Cover Image of:  Statistical Communications in Infectious Diseases

Statistical Communications in Infectious Diseases

Editor In Chief: Scott Evans

Free Trial Access Available!

Free Access Token

Register with De Gruyter Online and get access to this and other selected journals. Simply register with De Gruyter Online, log in and go to your personal user account "My De Gruyter". Please enter your access token FREE-ACCESS into the field provided. Once you have redeemed your token, you will be able to access the free content via the respective journal page.

Readers of Statistical Communications in Infectious Diseases have free access to its articles. To access the articles, simply click on "Get access to full text" on any article you wish to view.

You can enjoy access to a number of De Gruyter economics journals. To enjoy access, click here.

Your benefits
  • Answering some of the most urgent issues of today
  • Multidisciplinary approach
  • Innovative methodologies
  • Theoretical and practical outlook on infectious diseases
  • High educational value of published materials

The mission of Statistical Communications in Infectious Diseases is to serve as the primary vehicle for the communication and education of statistical thinking in infectious disease research and policy.

The infectious diseases community faces many difficult challenges. These include: (1) coping with continuing high-impact diseases such as HIV, malaria, TB, and flu; (2) dealing with infectious disease outbreaks such as Ebola, pandemic avian influenza, or SARS; and (3) preparing for the inevitable emergence of diseases that are unknown or are recognized but will reemerge in a more threatening form (e.g., antibiotic resistant [nightmare] bacteria or superbugs). Research in infectious diseases is also challenged by funding limitations, politics, and ethical dilemmas.

Increasingly complex data is also creating new challenges to the design and analysis of research studies. Enhanced statistical expertise is essential to address these challenges and to develop and evaluate medical and public health responses to potential outbreaks and epidemics.

Statistical Communications in Infectious Diseases (SCID) publishes significant research on the application of statistical ideas to problems arising from studies of infectious diseases. SCID takes a broad perspective on the role of statistics in infectious disease research including application, policy, education and theory. SCID fosters much-needed communication among statisticians on the best approaches to evolving complex infectious disease data, and is a venue for statisticians to enter a dialogue with other scientists and policy makers on the strengths and limitations of policies and methods for design, monitoring, analysis, and reporting of infectious disease research studies.

SCID goes beyond the application of statistical methods to data arising from infectious disease studies or new statistical strategies. SCID serves as a sounding board to discuss policy issues, as well as to accomplish the following goals: (1) engage and raise the quality of the discussions of important issues in the public and scientific press; (2) ensure that optimal scientific tools are utilized in infectious disease research; (3) improve the training and practice of the next generation of professionals involved in infectious diseases research through educational articles; (4) raise the profile of quantitative science in infectious disease research by demonstrating its value in decision making and public health.

  • How heavily should the public invest in research or implementation of different prevention modalities?
  • What is necessary to achieve control of epidemics (for example, do we require a vaccine to control the spread of HIV or what procedures are required to halt the spread of Ebola)?
  • How can statisticians help with grass roots epidemic control efforts?
  • How can we optimally evaluate the benefits vs. harms vs. costs of competing interventions?
  • How can we best characterize the trade-offs between civil liberties and public safety?
  • How should we adjust the traditionally required level of evidence to address areas of unmet medical need?
  • How do we revise our traditional approaches to the design, monitoring, analyses, and reporting of infectious disease studies to improve medical practice and public health?

Article formats
Original research articles, book reviews

Information on Submission Process

Abstracting & Indexing

Statistical Communications in Infectious Diseases is covered by the following services:

  • Baidu Scholar
  • Cabells Journalytics
  • CABI (over 50 subsections)
  • Case
  • CNKI Scholar (China National Knowledge Infrastructure)
  • CNPIEC - cnpLINKer
  • Current Index to Statistics
  • Dimensions
  • EBSCO (relevant databases)
  • EBSCO Discovery Service
  • Genamics JournalSeek
  • Google Scholar
  • Japan Science and Technology Agency (JST)
  • J-Gate
  • JournalGuide
  • JournalTOCs
  • KESLI-NDSL (Korean National Discovery for Science Leaders)
  • Mathematical Reviews (MathSciNet)
  • Meta
  • Microsoft Academic
  • MyScienceWork
  • Naver Academic
  • Naviga (Softweco)
  • Norwegian Register for Scientific Journals, Series and Publishers
  • Primo Central (ExLibris)
  • ProQuest (relevant databases)
  • Publons
  • QOAM (Quality Open Access Market)
  • ReadCube
  • Semantic Scholar
  • Sherpa/RoMEO
  • Summon (ProQuest)
  • TDNet
  • Ulrich's Periodicals Directory/ulrichsweb
  • WanFang Data
  • WorldCat (OCLC)
  • Yewno Discover
  • zbMATH

Supplementary Materials

Online Submission of Manuscripts

Your benefits of publishing with us

Submission process
  • Please submit your manuscript via our Online Submission Tool following the Instructions for Authors
  • Publication for all papers accepted after peer reviewing procedure
  • In case of any problems editorial assistance will be provided

Please note
  • Contributions submitted to this journal must be written in clear and concise English
  • Before submitting a paper please get familiar with our Publication Ethics and Malpractice Statement as well as Copyright Agreement
  • Once your article is accepted you have the option to publish it open access
  • Our repository policy allows you to distribute 30 PDF copies of your published article to colleagues (the PDF has to include the information that it is an author's copy). Please also feel free to distribute the link to the online abstract
  • If you have any general questions please visit our FAQ page for authors

We look forward to receiving your manuscript!

Scott R. Evans, Director of the George Washington Biostatistics Center, Milken Institute of Public Health, George Washington University, USA (sevans@bsc.gwu.edu)

Alfred Balch, University of Utah (Alfred.Balch@hsc.utah.edu)
Brad J. Biggerstaff, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, USA (bkb5@cdc.gov)
Ron Bosch, Harvard T.H.Chan School of Public Health (ronbosch@sdac.harvard.edu)
Ivan S.F. Chan, Abbvie Inc., USA (ivan.chan@abbvie.com)
Xiao Ding, Vir Inc., USA (xding@vir.bio)
Marion Ewell, The Emmes Corporation, USA (mewell@emmes.com)
Dean Follmann, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA (DFollmann@niaid.nih.gov)
Ron Fricker, Virginia Tech USA, (fricker@vt.edu)
Yonghong Gao, Biomedical Advanced Research and Development Authority, USA (Yonghong.Gao@hhs.gov)
Toshimitsu Hamasaki, George Washington University, USA (hamasaki@bsc.gwu.edu)
Honghu Liu, University of California Los Angeles (hhliu@ucla.edu)
Judith Lok, Boston University, USA (jlok@math.bu.edu)
Rhoderick Neri Machekano, Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA (rmachekano@pedaids.org)
Olga Marchenko, Quintiles, USA (Olga.marchenko@quintiles.com)
Suzanne May, University of Washington, USA (sjmay@uw.edu)
Devan Mehrotra, Merck, Inc., (devan_mehrotra@merck.com)
Farzad Noubary, Northeastern University (f.noubary@northeastern.edu)
Dionne L. Price, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA (Dionne.Price@fda.hhs.gov)
Cavan Reilly, Division of Biostatistics, School of Public Health, University of Minnesota, USA (cavanr@biostat.umn.edu)
Barbra Richardson, Department of Biostatistics, University of Washington, USA (barbrar@uw.edu)
Dan Rubin, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA (Daniel.Rubin@fda.hhs.gov)
Pamela Shaw, Department of Biostatistics and Epidemiology, University of Pennsylvania, USA (shawp@mail.med.upenn.edu)
Norma Terrin, Tufts University School of Medicine (Nterrin@tuftsmedicalcenter.org)
Lu Tian, Department of Health Research and Policy, Stanford University, USA (lutian@stanford.edu)
Kohei Uemura, Tokyo University, Japan (kohei.uemura@iii.u-tokyo.ac.jp)
Handan Wand, University of New South Wales, The Kirby Institute, Australia (Hwand@kirby.unsw.edu.au)
Rui Wang, Harvard Pilgrim Health Care, USA (ruiwang29@gmail.com)
Hulin Wu, University of Texas Health Science Center at Houston USA (Hulin.Wu@uth.tmc.edu)

Clinical Editors
Henry F. Chambers, Division of Infectious Diseases, University of California San Francisco, USA (Henry.Chambers@ucsf.edu)
Anthony Harris, University of Maryland School of Medicine, USA (aharris@epi.umaryland.edu)

Column Editors
Norberto Pantoja-Galicia, Office of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration, USA (Norberto.Pantoja-Galicia@fda.hhs.gov)
Gene Pennello, U.S. Food and Drug Administration, USA (Gene.Pennello@fda.hhs.gov)




Researchers, practitioners, educators, policy makers, students, and institutions interested in infectious diseases